Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

NCT03482752 is registered in ClinicalTrials.gov with Savara Inc. as lead sponsor.

NCT NCT03482752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03482752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
Lead sponsor
Savara Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 16, 2018
Completion date
January 14, 2021
Enrollment
60 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune pulmonary alveolar proteinosis